This book focuses on some of the new clinical and biological insights related to HIV-associated
metabolic and cardiovascular complications in the HAART era. The introduction of highly active
antiretroviral therapy (HAART) has altered cardiovascular manifestations in HIV. On the one
hand HAART has significantly improved the quality of life of HIV-infected patients. On the
other hand the early data have raised some concerns creating an intriguing clinical scenery.
